SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-134284
Filing Date
2024-05-08
Accepted
2024-05-08 16:41:03
Documents
15
Period of Report
2024-05-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d835346d8k.htm   iXBRL 8-K 24192
2 EX-99.1 d835346dex991.htm EX-99.1 20467
6 GRAPHIC g835346g0508234622019.jpg GRAPHIC 2866
  Complete submission text file 0001193125-24-134284.txt   177424

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20240508.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20240508_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20240508_pre.xml EX-101.PRE 11251
18 EXTRACTED XBRL INSTANCE DOCUMENT d835346d8k_htm.xml XML 3653
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 24926938
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)